Adial Pharmaceuticals granted key patent from USPTO

Adial Pharmaceuticals announced patent number 11957664 was issued April 16, 2024 by the United States Patent and Trademark Office, USPTO. This patent expands Adial’s intellectual property protection and covers the combination of the Company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder and other drug dependencies, such as opioid use disorder, with the Company’s lead investigational new drug product AD04. Cary Claiborne, CEO of Adial, commented, “We are proud to have secured this new patent, which covers important aspects of the combination of our proprietary genetic diagnostic and AD04 to treat AUD, OUD, and other drug dependencies. Importantly, we have identified specific genotypes that have responded with clinically meaningful changes in drinking behavior compared to placebo in the AD04 post hoc analysis, which represents an addressable market of approximately $40 billion in the U.S. alone. We believe our unique personalized approach can offer new hope to the millions affected by AUD, OUD and other addictive disorders such as obesity and gambling.”